Project Details
Projekt
Advanced CAR T cell engineering to augment the graft-versus-leukemia effect of allogeneic HSCT (A03)
Subject Area
Hematology, Oncology
Immunology
Immunology
Term
since 2018
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 324392634
We have developed CAR T cells that can be used as a ‘bridge to transplant’ (pre-HSCT) or to reinforce the GvL effect as a ‘CAR donor lymphocyte infusion’ (post-HSCT) for the treatment of acute myeloid leukemia and multiple myeloma. To refine these products for clinical translation, we will apply advanced techniques that prevent acute and chronic toxicity from cytokine release syndrome (CRS) and GvHD, and augment efficacy by preventing CAR T cell exhaustion and tumor immune escape. This will be accomplished with a pharmacologic CAR ON/OFF switch (Aim 1), precision CAR gene-transfer into the T-cell receptor gene locus (Aim 2), and combination therapy with microbial metabolites (Aim 3).
DFG Programme
CRC/Transregios
Subproject of
TRR 221:
Modulation of graft-versus-host and graft-versus-leukemia immune responses after allogeneic stem cell transplantation
Applicant Institution
Universität Regensburg
Project Heads
Professor Dr. Hermann Einsele; Professor Dr. Michael Hudecek
